Table 4.
Characteristics of myeloma patients with a lysoglucosylceramide (LGL1)-specific monoclonal IgA.
| Patient X03 | Patient X08 | Patient Nvs37 | |
|---|---|---|---|
| Sex (M/F) | F | F | M |
| Age (year) | 76 | 66 | 51 |
| Leukocytes (×109/L) | 2.4 | 7.2 | NA |
| Hemoglobin (g/dl) | 6.9 | 12.8 | NA |
| Platelets (×109/L) | 191 | 269 | NA |
| Bone marrow plasma cells (%) | 51 | 16 | NA |
| Calcemia (mmol/L) | 2.16 | 2.36 | NA |
| Creatinin (μmol/L) | 66 | 38 | NA |
| β2-microglobulin (mg/L) | NA | NA | NA |
| Monoclonal IgA (g/L) | 28.0 | 8.0 | 23.2 |
| Bone lesions | Yes | Yes | NA |
| ISS stage | NA | NA | NA |
| DSS stage | NA | III | NA |
| Serum IgA sialyation (%) | 36.1% | 46.3% | NA |
NA, not available; ISS, International System Staging; DSS, Durie–Salmon Staging.